1. Home
  2. IDE vs RNA Comparison

IDE vs RNA Comparison

Compare IDE & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Voya Infrastructure Industrials and Materials Fund of Beneficial Interest

IDE

Voya Infrastructure Industrials and Materials Fund of Beneficial Interest

HOLD

Current Price

$13.41

Market Cap

203.7M

Sector

Finance

ML Signal

HOLD

Logo Avidity Biosciences Inc.

RNA

Avidity Biosciences Inc.

HOLD

Current Price

$11.53

Market Cap

222.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IDE
RNA
Founded
2010
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
203.7M
222.5M
IPO Year
N/A
2025

Fundamental Metrics

Financial Performance
Metric
IDE
RNA
Price
$13.41
$11.53
Analyst Decision
Buy
Analyst Count
0
20
Target Price
N/A
$69.26
AVG Volume (30 Days)
29.1K
207.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
8.83%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$88.12
Revenue Next Year
N/A
$18.11
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.36
$11.40
52 Week High
$14.30
$73.06

Technical Indicators

Market Signals
Indicator
IDE
RNA
Relative Strength Index (RSI) 42.59 35.95
Support Level $13.27 $11.40
Resistance Level $13.95 $14.05
Average True Range (ATR) 0.24 0.45
MACD -0.02 -0.10
Stochastic Oscillator 39.02 1.56

Price Performance

Historical Comparison
IDE
RNA

About IDE Voya Infrastructure Industrials and Materials Fund of Beneficial Interest

Voya Infrastructure, Industrials and Materials Fund is a diversified closed-end management investment company. The primary objective of this investment fund is to achieve total return by combining current income, capital gains, and capital appreciation. To achieve this objective, the fund invests in companies that own and/or operate infrastructure facilities in the infrastructure sector, as well as in a broad range of companies in the industrials and materials sectors that the Sub-Adviser believes will benefit from infrastructure building, renovation, expansion, and utilization.

About RNA Avidity Biosciences Inc.

Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.

Share on Social Networks: